Patient safety is Roche/Genentech’s highest priority and we are closely monitoring the evolving coronavirus disease (COVID-19) situation. We believe that treatment decisions should be made between a patient and their treating neurologist/healthcare professional based on a benefit/risk assessment specific to the individual patient.
COVID-19 is caused by a new strain of coronavirus called SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2), so knowledge about how it may affect people with multiple sclerosis (MS) and those treated with ocrelizumab is currently unavailable.
Like many other disease-modifying therapies for MS, ocrelizumab works by making changes to the immune system.
Per the ocrelizumab European Summary of Product Characteristics (SmPC; Section 4.8):
In the active-controlled studies in RMS, infections occurred in 58.5% of patients receiving Ocrevus vs 52.5% of patients receiving interferon beta 1a. Serious infections occurred in 1.3% of patients receiving Ocrevus vs 2.9% of patients receiving interferon beta 1a. In the placebo-controlled study in PPMS, infections occurred in 72.2% of patients receiving Ocrevus vs 69.9% of patients receiving placebo. Serious infections occurred in 6.2% of patients receiving Ocrevus vs 6.7% of patients receiving placebo. An increase in the rate of serious infections was observed in RMS between Years 2 and 3, but not in subsequent years. No increase was observed in PPMS.
Ocrelizumab administration must be delayed in patients with an active infection until the infection is resolved.
Indications vary in different countries. The local prescribing information from your country is the primary source of information on the known and potential risks associated with ocrelizumab.